Evidence map›Paper›PMID 36339665›Full record

ArticleKidney medicine2022

Immunosuppression Exposure and Risk of Infection-Related Acute Care Events in Patients With Glomerular Disease: An Observational Cohort Study.

Dorey A Glenn, Jarcy Zee, Sarah Mansfield, Michelle M O'Shaughnessy, Andrew S Bomback, Keisha Gibson, Larry A Greenbaum, Laura Mariani, Ronald Falk, Susan Hogan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Dorey A GlennUniversity of North Carolina, Chapel Hill, North Carolina.
Jarcy ZeeThe Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Sarah MansfieldArbor Research Collaborative for Health, Ann Arbor, Michigan.
Michelle M O'ShaughnessyUniversity College Cork, Cork, Ireland.
Andrew S BombackColumbia University, New York, New York.
Keisha GibsonUniversity of North Carolina, Chapel Hill, North Carolina.
Larry A GreenbaumEmory University and Children's Healthcare of Atlanta, Atlanta, Georgia.
Laura MarianiUniversity of Michigan, Ann Arbor, Michigan.
Ronald FalkUniversity of North Carolina, Chapel Hill, North Carolina.
Susan HoganUniversity of North Carolina, Chapel Hill, North Carolina.
Amy MottlUniversity of North Carolina, Chapel Hill, North Carolina.
Michelle R DenburgThe Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Cure Glomerulonephropathy Network Consortium
University of North Carolina at Chapel Hill · USChildren's Hospital of Philadelphia · USArbor Research Collaborative for Health · USColumbia University · USEmory University · USUniversity College Cork · IEUniversity of Michigan · US

Funding

CureGNU24DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CRYSTAL A. GADEGBEKU, Laura H Mariani · 2019 to 2026
$12.1M
Research Project Core 2P50DK114786 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI Razzaghi Hanieh · 2017 to 2026
$9.6M
The Columbia PCC for CureGN: the Cure Glomerulonephropathy networkU01DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Andrew Stephen Bomback, ALI G GHARAVI · 2019 to 2026
$8.5M
CureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3M
CUREGN 3.0 - Pediatric Nephrology Consortium - PCCU01DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Laurence A Greenbaum, Jon Klein · 2019 to 2026
$7.7M
CureGN-3: UNCPCCU01DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Vimal Kumar Derebail, Ronald J Falk · 2019 to 2026
$6.7M
GDPrimeUM1DK100845 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S, KRETZLER, MATTHIAS · 2013 to 2018
$6.4M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
Integrative Proteomics & Metabolomics for Pediatric Glomerula Disease BiomarkersUM1DK100866 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GREENBAUM, LAURENCE A, SMOYER, WILLIAM E · 2013 to 2018
$5.5M
Advancing Clinical Research in Primary Glomerular Diseases (UM1)UM1DK100876 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GHARAVI, ALI G · 2013 to 2018
$4.8M
GDCN Clinical Center-Advancing Clinical Research in Primary Glomerular DiseasesUM1DK100867 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALK, RONALD J · 2013 to 2018
$4.0M
Protecting Patients with Glomerular Disease from Vaccine-Preventable InfectionsK23AI159073 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Dorey Glenn · 2022 to 2026
$988k
NIAID NIH HHS K23 AI159073NIDDK NIH HHS P50 DK114786NIDDK NIH HHS U01 DK100846NIDDK NIH HHS U01 DK100866NIDDK NIH HHS U01 DK100867NIDDK NIH HHS U01 DK100876NIDDK NIH HHS U24 DK100845NIDDK NIH HHS UM1 DK100845NIDDK NIH HHS UM1 DK100846NIDDK NIH HHS UM1 DK100866NIDDK NIH HHS UM1 DK100867NIDDK NIH HHS UM1 DK100876
6 · The paper itself

Abstract

Rationale & Objective: Infections cause morbidity and mortality in patients with glomerular disease. The relative contributions from immunosuppression exposure and glomerular disease activity to infection risk are not well characterized. To address this unmet need, we characterized the relationship between time-varying combinations of immunosuppressant exposure and infection-related acute care events while controlling for disease activity, among individuals with glomerular disease. Study Design: Prospective, multicenter, observational cohort study. Setting & Participants: Adults and children with biopsy-proven minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or immunoglobulin A nephropathy/vasculitis were enrolled at 71 clinical sites in North America and Europe. A total of 2,388 Cure Glomerulonephropathy Network participants (36% aged <18 years) had at least 1 follow-up visit and were included in the analysis. Exposures: Immunosuppression exposure modeled on a weekly basis. Outcome: Infections leading to an emergency department visit or hospitalization. Analytical Approach: Marginal structural models were used to estimate the effect of time-varying immunosuppression exposure on hazard of first infection-related acute care event while accounting for baseline sociodemographic and clinical factors, and time-varying disease activity. Results: A total of 2,388 participants were followed for a median of 3.2 years (interquartile range, 1.6-4.6), and 15% experienced at least 1 infection-related emergency department visit or hospitalization. Compared to no immunosuppression exposure, steroid exposure, steroid with any other immunosuppressant, and nonsteroid immunosuppressant exposure were associated with a 2.65-fold (95% CI, 1.83-3.86), 2.68-fold (95% CI, 1.95-3.68), and 1.7-fold (95% CI, 1.29-2.24) higher risk of first infection, respectively. Limitations: Absence of medication dosing data, lack of a control group, and potential bias in ascertainment of outcome events secondary to the coronavirus 2 pandemic. Conclusions: Corticosteroids with or without concomitant additional immunosuppression significantly increased risk of infection leading to acute care utilization in adults and children with glomerular disease.

Indexed as

Corticosteroidsglomerular diseaseglomerulonephritishospitalizationimmunosuppressioninfection

Identifiers

PMID36339665
PMCPMC9630793
OpenAlexW4298325912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.